Fixed combination of shared cancer antigens

  • Concept: Cancer immunotherapies targeting shared antigens that we have identified to be frequently expressed across patients with a specific cancer type.
  • mRNA Format: Optimized mRNA providing superior immunogenicity.
  • mRNA Delivery Formulation: Proprietary size- and charge-based RNA-LPX targeting DCs.
  • Development Approach: Worldwide rights; wholly owned.
  • Lead Candidate: BNT111 for metastatic melanoma.
  • Data Highlights: Four partial responses and eight stable diseases in 22 patients with metastatic lesions at enrollment, following BNT111 monotherapy.

More about FixVac

Product Drugclass
Short Description
Fixed combination of shared cancer antigens
Product Typology

We look forward to connecting with you

Temp JS

p4-css-global

p4-css-templates-a

p4-css-templates-b

Temp JS

p4-css-global

p4-css-templates-a

p4-css-templates-b